TScan Therapeutics Q1 EPS $(0.67) Up From $(6.49) YoY
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.67) per share. This is a 89.68 percent increase over losses of $(6.49) per share from the same period last year.
HC Wainwright & Co. Initiates Coverage On TScan Therapeutics with Buy Rating, Announces Price Target of $21
HC Wainwright & Co. analyst Andrew Fein initiates coverage on TScan Therapeutics (NASDAQ:TCRX) with a Buy rating and announces Price Target of $21.
TScan Therapeutics Announces Poster Presentations At 63rd American Society Of Hematology Annual Meeting And Exposition
- Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 -
- Phase 1 clinical trial expected to initiate in
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.
58 Biggest Movers From Yesterday
Gainers
MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the company will buy ZACC Kabushiki Kaisha for $3.362 million.
38 Stocks Moving In Thursday’s Mid-Day Session
Gainers
MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares jumped 101% to $14.87 following news the company will buy ZACC Kabushiki Kaisha for $3.362 million.